Welcome to our dedicated page for Tff Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (TFFP) has been described in its public communications as a clinical-stage biopharmaceutical company built around its proprietary Thin Film Freezing (TFF) technology platform. Over time, the company has issued news covering its inhaled dry powder product candidates, collaborations with academic and government partners, and later, significant corporate developments related to winding down operations and delisting from Nasdaq.
Earlier news from TFF Pharmaceuticals has focused on the progress of its TFF-based pipeline. This includes updates on tacrolimus inhalation powder (TFF TAC) for the prevention of lung transplant rejection, where the company has reported Phase 2 clinical data on safety, pharmacokinetics, biomarker outcomes, and patient enrollment. Additional releases have highlighted preclinical data for TFF-formulated influenza vaccine candidates and work on inhaled or intranasal dry powder formulations designed to address respiratory viral infections, including influenza and COVID, often in collaboration with institutions such as Emory University and Cleveland Clinic and with support from U.S. government agencies.
News items have also described the broader capabilities of the Thin Film Freezing platform, including its application to vaccines, small and large molecules, and biologics, and its potential to create temperature-stable dry powders suitable for inhalation or topical delivery. Corporate updates have included financial results, regulatory interactions with the U.S. Food and Drug Administration regarding the TFF TAC program, and the engagement of advisors to explore partnership and licensing opportunities.
More recent announcements mark a shift in focus, with TFF Pharmaceuticals disclosing the termination of its employees, a decision to wind down operations, and plans for liquidation and dissolution. The company has also announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market, stating that this step is being taken in connection with the planned liquidation. This news page provides a record of both the scientific and clinical developments associated with the TFF platform and the subsequent corporate decisions affecting the company’s trading status and future.
TFF Pharmaceuticals and Leidos are advancing next-generation biodefense countermeasures under the DARPA PPB Program into preclinical testing.
These countermeasures, formulated using TFF's Thin Film Freezing (TFF) technology, have shown neutralizing activity against chemical and biological threats in vitro and ex vivo models.
The collaboration aims to protect military and healthcare personnel from future threats. The preclinical testing will be conducted at DARPA-contracted labs.
TFF's CEO Dr. Harlan Weisman highlighted the progress with Leidos and the potential of TFF technology to develop needle-free, temperature-independent solutions.
TFF Pharmaceuticals, in collaboration with Cleveland Clinic, announced the advancement of multiple multivalent universal influenza vaccines into preclinical testing. Utilizing TFF's Thin Film Freezing technology, these vaccines aim to protect against seasonal and pandemic flu viruses. The preclinical testing decision follows successful formulation testing and stability data on hemagglutinin (HA) antigens with four adjuvants. Funded by NIAID, this work aims to create a universal, shelf-stable, and easy-to-transport vaccine, potentially advancing to human clinical trials. The research targets a vaccine that circumvents cold chain storage needs and improves distribution. TFF received a $2.97M SBIR grant in June 2023 for this project, highlighting its potential efficacy and protection against influenza A viruses.
TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension phase. One patient has been on treatment for over a year, and three others for more than six months.
The initial pharmacokinetic (PK) data shows reduced systemic variability with TFF TAC, potentially lowering risks of acute rejection and systemic toxicities. Positive feedback includes reduced headaches and improved wellness. A more detailed clinical update is expected later in the year.
TFF Pharmaceuticals (NASDAQ: TFFP) announced its first quarter 2024 financial results, highlighting significant advances in clinical development. The company raised $6.0 million, supporting the progression of its Tacrolimus Inhalation Powder (TFF TAC) for lung transplant recipients. Recent data from the Phase 2 trial showed TFF TAC's potential in preventing organ rejection with favorable safety outcomes. The company submitted a study plan to the FDA and expects feedback in the second quarter. Financially, TFF Pharmaceuticals reported a net loss of $5.7 million, down from $7.1 million in the previous year. R&D expenses decreased by 12%, and G&A expenses fell by 22%. Cash and equivalents stood at $3.2 million as of March 31, 2024.
TFF Pharmaceuticals, Inc (Nasdaq: TFFP) closed a public offering, raising approximately $4.8 million by selling shares and warrants. The company plans to use the net proceeds for general corporate purposes and working capital.
TFF Pharmaceuticals, Inc. announced a public offering of 1,665,219 shares of common stock and warrants, priced at $2.875 per share, with gross proceeds estimated at $4.8 million. The Company plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on May 1, 2024.
TFF Pharmaceuticals has released Phase 2 data from Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. Results show TFF TAC can prevent rejection at lower doses than oral tacrolimus, reducing systemic exposures and toxicities. Gene expression data indicate TFF TAC normalizes rejection-related genes, potentially improving efficacy and safety post-transplant.
Summary not available.
Summary not available.
Summary not available.